Vancomycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vancomycin: From Bacterial Infections to Diffuse Scleroderma
One-Sentence Summary
Vancomycin is a glycopeptide antibiotic historically used to treat serious Gram-positive bacterial infections (e.g., MRSA); this evidence pack does not contain a formal approved-indication text or MOA record for the drug (see Data Gaps below). TxGNN’s top-ranked prediction is Diffuse Scleroderma, an autoimmune fibrotic disease, but the accompanying evidence review found no supporting clinical trials and only 1 tangentially related case-report publication, with the mechanistic analysis explicitly judging the link not pharmacologically plausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no license/approved-indication text on file; drug is currently unmarketed in this jurisdiction) |
| Predicted New Indication | Diffuse Scleroderma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for vancomycin in this evidence pack (flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge, vancomycin is a glycopeptide antibiotic that inhibits bacterial cell-wall synthesis by binding the D-Ala-D-Ala terminus of peptidoglycan precursors in Gram-positive organisms — a mechanism with no known relevance to fibrotic or autoimmune connective-tissue disease.
Diffuse scleroderma is a fibrotic autoimmune disorder driven by aberrant fibroblast activation and collagen deposition, not by bacterial infection. The domain-expert rationale attached to this candidate explicitly states there is no reasonable mechanistic link: the only supporting literature is a case report of erythroderma with sepsis in which vancomycin was used to treat a secondary bacterial complication, not the underlying dermatologic/fibrotic condition itself. This strongly suggests the high TxGNN embedding score reflects a knowledge-graph artifact (over-generalized “antibiotic–skin/systemic disease” associations) rather than a biologically grounded repurposing signal.
Given the absence of mechanistic rationale, clinical trial evidence, and even the drug’s own basic regulatory/MOA documentation, this candidate should be treated as a low-confidence, model-only signal rather than a credible repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31541072 | 2019 | Case Report | The American Journal of Case Reports | Case of exfoliative erythroderma with sepsis and eosinophilia; vancomycin was used as antimicrobial therapy for a secondary bacterial complication, not as treatment for the underlying dermatologic condition itself. No direct evidence for a scleroderma indication. |
US Market Information
No marketing authorizations are on record for this drug in this evidence pack (Market Status: Not Marketed, 0 licenses/NDAs).
Safety Considerations
Please refer to the package insert for safety information.
Note: A Blocking-severity data gap (DG001) has been identified — regulatory warnings and contraindication text for this drug have not yet been retrieved, which prevents formal S1 safety screening.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Diffuse Scleroderma) has Evidence Level L5 (model prediction only) — no clinical trials support it, only one indirectly related case report exists, and the mechanistic review explicitly found no plausible pharmacological rationale linking vancomycin’s antibacterial mechanism to a fibrotic autoimmune disease. Combined with the drug’s unmarketed status and a Blocking-severity safety data gap, there is currently insufficient evidence to advance this candidate.
To proceed, the following is needed:
- Vancomycin’s official warnings/contraindications (DG001, Blocking) — required before any S1 safety screening
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- A biologically grounded hypothesis connecting vancomycin’s mechanism to scleroderma pathophysiology (currently absent)
- Preclinical or observational evidence beyond the single unrelated case report before any further evaluation is warranted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.